Current status of TAFRO syndrome

Abstract

TAFRO syndrome is characterized by thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organ enlargement, which is acute or subacute onset. Its current etiopathogenisis remains unclear. It is considered to be a specific subtype of Castleman disease. Due to the low incidence and few case reports, there is not enough understanding of TAFRO syndrome. Early detection, accurate diagnosis, timely and effective treatments are the key points to improve the survival rate of patients with TAFRO syndrome. Here, this article summarizes the diagnosis and treatments of TAFRO syndrome and review the research progress. The goal of this article is to help clinicians have a better understanding of TAFRO syndrome, so that TAFRO syndrome can be diagnosed and treated in time. Key words: Giant lymph node hyperplasia; Castleman disease; TAFRO syndrome; Diagnosis; Therapeutics